CYP2C9 allelic variants and frequencies in a pediatric sickle cell disease cohort: Implications for NSAIDs pharmacotherapy

Clinical and Translational Science

Volumn 7, Issue 5, 2014, Pages 396-401

  Jaja, Cheedy ^a   Patel, Niren ^b   Scott, Stuart A ^c   Gibson, Robert ^d   Kutlar, Abdullah ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d AUGUSTA UNIVERSITY   (United States)

Author keywords

CYP2C9; Genotyping; NSAIDs; Pharmacogenetics; Sickle cell disease

Indexed keywords

CYTOCHROME P450 2C9; HYDROXYUREA; NONSTEROID ANTIINFLAMMATORY AGENT; CYP2C9 PROTEIN, HUMAN;

ADOLESCENT; AFRICAN AMERICAN; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MALE; MISSENSE MUTATION; MORBIDITY; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SICKLE CELL ANEMIA; ALLELE; ANEMIA, SICKLE CELL; DEMOGRAPHY; GENETICS;

ADOLESCENT; ALLELES; ANEMIA, SICKLE CELL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; COHORT STUDIES; CYTOCHROME P-450 CYP2C9; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; PHENOTYPE;

EID: 84911808190     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12172     Document Type: Article

References (24)

1. Field JJ, Knight-Perry JE, DeBaum MR. Acute pain in children and adult with sickle cell disease: management in the absence of guidelines. Curr Opin Hematol. 2009; 16: 173-178.
2. Niscola P, Sorrentino F, Scaramucci L, deFabritiis P, Cianciulli P. Pain syndromes in sickle cell disease: an update. Pain Med. 2009; 10: 470-80.
3. Jerrell JM, Tripathi A, Stallworth JR. Pain management in children and adolescents with sickle cell disease. Am J Hematol. 2011; 86: 82-84.
4. Wang B, Wang J, Huang SQ, Su HH, Zhou SF. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab. 2009; 10: 781-834.
5. Dills R, Anderson LA, Pierce AP. The role of nonsteroidal anti-inflammatory drugs in pediatric patients. Pharmacol Res. 2012; 65: 5-8.
6. De Wildt SN. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol. 2011; 7: 935-948.
7. Sim SC, Ingelman-Sundberg M. The human cytochrome P450 Allele Nomenclature Committee Website: submission criteria, procedures, and objectives. Methods Mol Biol. 2006; 320: 183-191.
8. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9*8 is prevalent among African-American: implications for pharmacogenetic dosing. Pharmacogenomics. 2009; 10: 1243-1255.
9. Man N, Farme M, Dumaual C, Teng CH, Moser B, Close S, Wise S, Hockett R. Genetic variation in metabolizing enzymes and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and African. J Clin Pharmacol. 2010; 50: 929-940
10. Kudzi W, Dodoo A, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 in a Ghanaian population. BMC Med Genet. 2009; 10: 124.
11. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010; 11: 781-791.
12. Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003; 56: 653-657.
13. Vargens DD, Damasceno A, Petzl-Erler M, Suarez-Kurtz G. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans, and Brazilians. Pharmacogenomics. 2011; 12: 769-772.
14. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmöller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther. 2002; 72: 62-75.
15. García-Martín E, Martínez C, Tabarés B, Frías J, Agúndez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther. 2004; 76: 119-127.
16. Bae JW, Kim JH, Choi CI, Kim MJ, Kim HJ, Byun SA, Chang YS, Jang CG, Park YS, Lee SY. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects. Arch Pharm Res. 2009; 32: 269-273.
17. Martínez C, Blanco G, Ladero JM, García-Martín E, Taxonera C, Gamito FG, Diaz-Rubio M, Agúndez JA. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004; 141: 205-208.
18. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, Niro V, Andriulli A, Leandro G, Di Mario F, Dallapiccola B. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007; 133: 465-471.
19. Becker Ml, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose of sulfonylurea in Type II diabetes mellitus. Clin Pharmacol Ther. 2003; 83: 288-292.
20. Higashi Mk, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetics variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287: 1690-1698.
21. Loovers HM, Van der Weide J. Implementation of CYP2D6 genotyping in psychiatry. Expert Opin Drug Metab Toxicol. 2009; 5: 1-13.
22. Joly P, Gagnieu MC, Bardel C, Francina A, Pondarre C, Martin C. Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. Am J Hematol. 2012; 87: 534-536.
23. Yee M, Josephson C, Hill C, Harrington R, Castillejo MI, Ramjit R, Osunkwo I. Cytochrome P450 2D6 polymorphism and predicted metabolism in African American children with sickle cell disease. J Pediatr Hematol Oncol. 2013; 7: e301-e305.
24. Shord SS, Cavallari LH, Gao W Jeong HY, Deyo K, Patel SR, Camp JR, Labott SM, Molokie RE. The pharmacokinetics of codeine and its metabolites in blacks with sickle cell disease. Eur J Clin Pharmacol. 2009; 65: 651-658.